Showing results (531-540 of 834) with videos related to
Sort By:
Pageof 84
NEJM Evidence|October 28, 2025
Cardiac Effects of Dapagliflozin in People with Chronic Kidney DiseaseKatja Vu Bartholdy, Niklas Dyrby Johansen, Kristoffer Grundtvig Skaarup, et al.Circulation|November 17, 2020
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 DiabetesGerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, et al.The New England Journal of Medicine|December 2, 2020
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 DiabetesGeorge L Bakris, Rajiv Agarwal, Stefan D Anker, et al.Circulation|November 15, 2021
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD TrialGerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, et al.JACC. Heart Failure|November 3, 2022
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and DiabetesGerasimos Filippatos, Stefan D Anker, Bertram Pitt, et al.Diabetes, Obesity & Metabolism|May 4, 2019
Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetesRegitse H Christensen, Christian S Hansen, Bernt Johan von Scholten, et al.International Journal of Molecular Sciences|February 26, 2025
Characterization of Anti-Insulin Antibodies in Type 1 and Type 2 Diabetes Mellitus: Clinical RelevanceHenrik Toft-Hansen, Christina Aniol-Nielsen, Daniel Elias, et al.Journal of Medical Economics|July 13, 2023
Estimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetesPeter Rossing, Franziska Groehl, Paul Mernagh, et al.Endocrine|May 17, 2023
Predicting the HbA1c level following glucose-lowering interventions in individuals with HbA1c-defined prediabetes: a post-hoc analysis from the randomized controlled PRE-D trialLea Bruhn, Dorte Vistisen, Hanan Amadid, et al.Journal of Diabetes and Its Complications|February 12, 2026
Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITYRobert Weingold, Gerasimos Filippatos, Stefan D Anker, et al.Pageof 84